KRAS oncogene, mutated in approximately 30%–50% of CRC patients [2], presents both as a prognostic and predictive marker for targeted therapy of CRC [3, 4], and mutations in KRAS results in non-response to anti-EGFR inhibitors [4–6]. This evidence concerns the gene EGFR and colorectal carcinoma.